Silexion Therapeutics Corp (SLXN) stock
SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
$1.65−0.11 (-6.25%)
Close on Nov 17, 2026Market cap $995.04KP/E –Yield –
Silexion Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Silexion Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $8.24M, up 77.8% year over year. For fiscal 2025 it was $7.14M, up 22.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.14M | +22.8% |
| FY2024 | Dec 31, 2024 | $5.82M | +56.8% |
| FY2023 | Dec 31, 2023 | $3.71M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.29M | -40.4% |
| Q2 FY2026 | Jun 30, 2026 | $2.21M | +117.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.37M | +132.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.38M | +287.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.16M | -32.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.02M | +32.9% |
| Q1 FY2025 | Mar 31, 2025 | $590.00K | -38.6% |
| Q4 FY2024 | Dec 31, 2024 | $871.00K | -30.7% |
| Q3 FY2024 | Sep 30, 2024 | $3.22M | +501.3% |
| Q2 FY2024 | Jun 30, 2024 | $766.00K | -38.0% |
| Q1 FY2024 | Mar 31, 2024 | $961.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $1.26M | – |
| Q3 FY2023 | Sep 30, 2023 | $535.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $1.24M | – |
See a number that looks wrong?